Program

 

 

Pre AASLD Session
Wednesday, 11 November 2020

 

 

10:00 AM
EDT

Opening of the Workshop

Harry Janssen MD, PhD

Toronto Centre for Liver Disease, Toronto, Canada

 
  Session Chairs

Scott Fung MD, FRCPC

Toronto General Hospital, Toronto, Canada

Anna Suk-Fong Lok MD
University of Michigan, Michigan, United States

 
 

10:05 AM
EDT

Potential of new combinations to achieve functional cure for Chronic Hepatitis B

Fabien Zoulim MD, PhD
Inserm, Lyon, France

 
 10:20 AM
EDT

Live Q&A

 
 10:25 AM
EDT

Rationale for including immune tolerant and low viral load patients in new drug trials

Henry Lik Yeun Chan MBChB, MD, FRCP, FAASLD, FHKCP, FHKAM
The Chinese University of Hong Kong, Hong Kong, China

 
 10:40 AM
EDT

Live Q&A

 
 10:45 AM
EDT
How to interpret flares in HBV trials with novel agents

 

Pietro Lampertico MD, PhD

University of Milan, Milan, Italy

 
 11:00 AM
EDT
Live Q&A 
 11:05 AM
EDT

Toxicity in new and established HBV compounds

Jordan Feld MD, MPH
Toronto Centre for Liver Disease, Toronto, Canada

 
 11:20 AM
EDT
Live Q&A 
 11:25 AM
EDT
Safety monitoring  for different drug classes and antiviral discontinuation

 

Poonam Mishra MD, MPH

US Food and Drug Administration, Washington, United States

 
 

11:40 AM
EDT

Live Q&A

 
 11:45 AM
EDT

Faculty Discussion

 
 12:15 PM
EDT

Closing of the Workshop

 

 

 

Post AASLD Session
Wednesday, 2 December 2020

 

 

10:00 AM
EDT

Opening of the Workshop

 

Harry Janssen MD, PhD

Toronto Centre for Liver Disease, Toronto, Canada

 
  Session Chairs

 

Mala Maini MD, PhD
University College London, London, United Kingdom

Norah Terrault MD, MPH, FAASLD
Keck School of Medicine of University of Southern California, Los Angelas, United States

 
 

10:05 AM
EDT

Update on new antiviral targets - Capsid Inhibitors

Kosh Agarwal MD
Kings College Hospital, London, United Kingdom

 
 10:20 AM
EDT

Live Q&A

 
 10:25 AM
EDT

Update on new antiviral targets - non-Capsid Inhibitors

Man-Fung Yuen DSc, MD, PhD
The University of Hong Kong, Hong Kong, China

 
 10:40 AM
EDT

Live Q&A

 
 10:45 AM
EDT
Update on new immuno modulators

 

Adam Gehring PhD

Toronto Centre for Liver Disease, Toronto, Canada

 
 11:00 AM
EDT
Live Q&A 
 11:05 AM
EDT

Update on Hepatitis Delta therapy

Robert Gish MD, FAASLD
University of California - San Diego, San Diego, United States

 
 11:20 AM
EDT
Live Q&A 
 11:25 AM
EDT
Update on novel combination strategies

 

Marion Peters MD
University of California - San Francisco, San Francisco, United States
 
 

11:40 AM
EDT

Live Q&A

 
 11:45 AM
EDT

Faculty Discussion

 
 12:15 PM
EDT

Closing of the Workshop